Tirzepatide, new hyperglycemia guideline among highlights for ADA annual meeting
Click Here to Manage Email Alerts
Tirzepatide, new hyperglycemia recommendations and mental health for people with diabetes are among the key topics that will be highlighted for the first in-person American Diabetes Association Scientific Sessions in 3 years.
The ADA 82nd Scientific Sessions, scheduled to run Friday through Tuesday, will take place at the Ernest N. Morial Convention Center in New Orleans. After hosting a fully virtual meeting for the past 2 years, this year’s meeting will be hybrid, with many of the major sessions and presentations livestreamed for remote attendees.
“We are incredibly excited to be in person,” Robert A. Gabbay, MD, PhD, FACP, chief scientific and medical officer for the ADA, told Healio. “There’s just another element of engagement and interaction that happens in person that we can’t quite do the same way virtually.”
The ADA has issued health and safety guidelines for in-person attendees. All attendees must be fully vaccinated for COVID-19 and will be required to submit proof of vaccination using a third-party app, VaxYes, before receiving their credentials for the meeting. Attendees must also wear a face mask at all times except when speaking, presenting, eating or drinking.
Attendees who opt to watch the meeting virtually will have access to 61 sessions across the 5-day event. Livestreamed sessions will be available to watch on demand the day after they air. A full list of livestreamed sessions is available on the meeting website.
“We learned a lot during the pandemic, including the value of having a virtual component, particularly for people that can’t travel,” Gabbay said. “It extends the reach of the meeting globally so much more effectively.”
The biggest focus among the new trial data being presented this year is on tirzepatide (Mounjaro, Eli Lilly). Last month, the FDA approved tirzepatide for treatment of adults with type 2 diabetes alongside diet and exercise. On Saturday at 9 a.m. CDT, researchers will present findings from SURMOUNT-1, the first phase 3 trial on the use of tirzepatide for adults with obesity. The data are expected to be published simultaneously in The New England Journal of Medicine.
The ADA has partnered with the European Association for the Study of Diabetes to unveil new guidelines for the treatment of hyperglycemia in type 2 diabetes. A draft version of the guideline will be discussed during a presentation Monday at 4:30 p.m. CDT to give attendees a chance to comment. A final form of the guideline is expected to be presented at the EASD annual meeting in September.
Mental health will be the focus of a session on Friday at 4:15 p.m. CDT. Katharine Barnard, PhD, a visiting professor at Southern Health NHS Foundation Trust in Southampton, U.K., and a panel of experts will discuss the risk for mental health issues, such as depression and suicide, among people with type 1 diabetes and strategies for reducing the mental health burden.
Other highlights of this year’s meeting:
- Findings from a trial analyzing the use of low-dose interlukin-2 in people recently diagnosed with type 1 diabetes will be presented on Saturday at 4 p.m. CDT. The presentation is the first data released from the trial.
- A symposium focused on defining and interpreting type 2 diabetes remission will take place on Monday at 4:30 p.m. CDT.
- Friday’s program wraps up with a networking reception at 6:30 p.m. CDT. Light hors d'oeuvres and refreshments will be served as attendees network with colleagues in person for the first time since 2019.
“We all have this hunger for being with our friends and colleagues,” Gabbay said. “If you look at how science advances, it’s those casual conversations that really make it happen. It historically has happened all over the halls of our Scientific Sessions. That initial networking event will be the kickoff.”
The Healio | Endocrine Today staff will provide coverage from the 82nd Scientific Sessions with reports on the presentations, video interviews and more. For more information on the ADA agenda and registration, visit professional.diabetes.org/scientific-sessions.
Collapse
Healio Interviews
Read more about
Click Here to Manage Email Alerts